Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesSleep MedicineAetna MSLT MWT Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0330

    Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT)

    Customize your policy alerts

    Sign up for Aetna Policy 0330 alerts

    Get alerted when Policy 0330 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, investigational status, and coding guidance for facility-based MSLT and MWT for evaluation of narcolepsy and idiopathic hypersomnia; applies to providers submitting claims to Aetna.

    Policy Summary
    PayerAetna
    PolicyMultiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT)
    Policy CodePolicy 0330
    Change TypeAnnual review — no material changes
    Effective DateApr 20, 1999
    Last ReviewMay 2, 2023
    Next Review DateMar 28, 2024
    Key ActionSubmit CPT 95805 only when selection criteria in the policy are met (MSLT/MWT covered for evaluation of narcolepsy or suspected idiopathic hypersomnia).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2indications considered medically necessary

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5
    nap trials in routine MSLT
    4nap trials in routine MWT
    95805primary CPT code for MSLT/MWT

    Coverage Criteria for MSLT and MWT

    inv-01: Medical Necessity Indications

    Covered when ANY of the following are met:

    Covered indications: Evaluation of symptoms of narcolepsy to confirm the diagnosis.

    Aetna considers MSLT and MWT medically necessary for evaluation of narcolepsy per policy and AASM guidance.

    Covered indications: Evaluation of persons with suspected idiopathic hypersomnia to help differentiate idiopathic hypersomnia from narcolepsy.

    Aetna considers MSLT and MWT medically necessary for this indication; consistent with AASM guidance.

    inv-02: Repeat Testing Criteria

    Repeat MSLT/MWT are NOT medically necessary UNLESS ALL of the following exception conditions apply (repeat permitted if any one exception applies):

    Repeat testing exceptions: Initial test was invalid or uninterpretable.

    Repeat testing allowed when initial study cannot be interpreted.

    Repeat testing exceptions: Initial test was affected by extraneous circumstances or appropriate study conditions were not present during initial testing.

    Repeat testing allowed when study conditions were inadequate.

    Repeat testing exceptions: Patient is suspected to have narcolepsy but earlier MSLT or MWT evaluation did not provide polygraphic confirmation.

    Repeat testing allowed to obtain polygraphic confirmation for suspected narcolepsy.

    inv-03: Experimental and Investigational

    MSLT and MWT are considered experimental and investigational (not covered) for the following and other non-listed indications:

    Investigational indications: Home MSLT (home-based MSLT has not been proven equivalent to formal in-lab MSLT).

    Home MSLT considered experimental per policy.

    Investigational indications: Single nap studies (a full MSLT or MWT is required for accurate diagnosis of narcolepsy).

    Single nap studies considered experimental per policy.

    Investigational indications: Assessment for attention-deficit/hyperactivity disorder (ADHD).

    Listed among indications lacking established effectiveness.

    Investigational indications: Chronic fatigue syndrome.

    inv-04: Evidence summaries and diagnostic thresholds

    Summaries of clinical evidence relevant to diagnostic interpretation and test utility:

    MSLT utility across populations: Pediatric NT1: a study of 357 children found mean MSLT sleep latency <= 8.2 minutes or >= 2 SOREMPs provided high diagnostic accuracy for narcolepsy type 1; these thresholds were valid and reliable markers in the pediatric cohort.<= 8.2 mins; >= 2 SOREMPs

    Use pediatric-specific thresholds and adjunctive data (PSG, CSF hypocretin, cataplexy) when available.

    MSLT utility across populations: Home-modified MSLT: randomized cross-over study showed no difference in mean sleep latency between unattended home and attended in-hospital MSLT, but home testing had a higher rate of 2+ SOREMPs; further study needed before home testing is adopted clinically.

    Home MSLT mean sleep latency comparable but SOREMP rates differed; clinical utility not established.

    MSLT utility across populations: Psychiatric hypersomnolence: systematic review found high heterogeneity and that approximately 25% of patients had mean sleep latency < 8 minutes (adult cut-point), highlighting limitations of MSLT for distinguishing psychiatric hypersomnolence from other CNS hypersomnias.

    MSLT and MWT are not routinely indicated for the initial evaluation of obstructive sleep apnea or for assessment of change following CPAP therapy. The policy also lists these tests as not routinely indicated for evaluation of sleepiness in medical and neurologic disorders (other than narcolepsy), insomnia, circadian rhythm disorders, and several other conditions reflected in the ICD-10 examples (for example, dementias, Parkinson's disease, primary insomnia, and obstructive sleep apnea) that are identified as not covered for the CPB indications.

    Home-based MSLT and single-nap studies are specifically considered experimental/investigational (not covered) because they have not been proven equivalent to formal, facility-based MSLT and a full MSLT or MWT is required for accurate diagnosis of narcolepsy.

    An UpToDate review on adult ADHD does not list MSLT as a management tool. The policy cites that UpToDate (Bukstein, 2016) does not recommend MSLT for routine use in the assessment or management of adult ADHD, and supporting primary studies reported no consistent difference in mean MSLT sleep latency between adults with ADHD and controls.

    Repeat MSLT and MWT are considered not medically necessary except when one or more of the following conditions applies: the initial test was invalid or uninterpretable; the initial test was affected by extraneous circumstances or required study conditions were not present; or the patient is suspected to have narcolepsy but earlier MSLT/MWT did not provide polygraphic confirmation.

    The policy notes that MSLT and MWT are facility-based studies performed under defined protocols (MSLT typically after a nocturnal PSG with at least six hours of sleep using five 20-minute nap trials separated by two-hour intervals; MWT typically uses four 40-minute trials). Single-nap studies and home MSLT are not acceptable substitutes for repeat in-lab testing and are considered experimental/investigational or not medically necessary when used to replace a full, facility-based study.

    Evidence assessing MSLT performance in psychiatric hypersomnolence is limited and heterogeneous. Early work (Nofzinger et al., 1991) found that patients with hypersomnia related to mood disorders did not show the REM-related daytime nap abnormalities typical of narcolepsy, and more recent systematic review data (Plante, 2016) show high heterogeneity with a pooled sleep propensity similar to normative values.

    Approximately 25% of patients with psychiatric hypersomnolence may demonstrate a mean sleep latency below the commonly used pathologic cut-point (8 minutes), underscoring that MSLT findings in psychiatric populations can overlap with other CNS causes of sleepiness and may not reliably distinguish psychiatric hypersomnolence from other disorders.

    Coding and Diagnostic Thresholds

    Covered CPT Codes (if selection criteria met)CPTCovered
    95805Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness.
    Other related CPT CodesCPT
    95782Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
    95806Sleep study.
    95807Sleep study.
    95808Polysomnography; sleep staging, attended by a technologist.
    95809Polysomnography; sleep staging, attended by a technologist.
    95810Polysomnography; sleep staging, attended by a technologist.
    95811Polysomnography; sleep staging, attended by a technologist.
    ICD-10 Codes covered if selection criteria are metICD-10Covered
    G47.10 - G47.19Hypersomnia
    G47.411 - G47.429Narcolepsy and cataplexy
    G47.53Recurrent isolated sleep paralysis
    R44.0 - R44.3Hallucinations
    R53.81 - R53.83Other malaise and fatigue [excessive or extreme sleepiness]
    ICD-10 Codes not covered for indications listed in the CPB (not all-inclusive)ICD-10Not Covered
    F01.50 - F03.91Dementias
    G20Parkinson's disease
    G47.33Obstructive sleep apnea (adult) (pediatric)
    G47.00Insomnia, unspecified
    Pediatric NT1 MSLT mean sleep latency threshold
    Pediatric NT1 MSLT mean sleep latency threshold<= 8.2 minutes (mean MSLT sleep latency) — optimal cutoff identified by ROC analysis for pediatric NT1
    Evidence sourceROC analysis in pediatric cohort (n=357) comparing CSF hypocretin-1 deficiency vs non-deficiency; AUC = 0.985 for mean latency <= 8.2 mins
    Clinical implicationMean sleep latency <= 8.2 mins on MSLT supports diagnosis of narcolepsy type 1 in children when interpreted with PSG, CSF hypocretin-1 and clinical features
    SOREMP threshold for pediatric NT1
    SOREMP count threshold>= 2 SOREMPs on MSLT (sleep-onset REM periods) — supports pediatric NT1 diagnosis

    Provider Actions, Billing, and Denial Risk

    Prior Authorization

    CPT 95805 covered when selection criteria met

    CPT 95805 (Multiple sleep latency or maintenance of wakefulness testing) is covered when the policy's selection criteria for MSLT/MWT are met.

    • Covered only for: 1) evaluation to confirm narcolepsy; or 2) evaluation to help differentiate idiopathic hypersomnia from narcolepsy.
    Note

    No explicit prior authorization procedures stated

    The document does not specify any explicit prior authorization requirements or list payer-level authorization triggers or affected billing codes beyond stating coverage conditions for CPT 95805.

    Step Therapy

    Background and Scope

    The Multiple Sleep Latency Test (MSLT) is a facility-based, objective measure of daytime sleepiness used primarily to confirm narcolepsy and to help differentiate idiopathic hypersomnia from narcolepsy. Routine MSLT protocol involves multiple daytime nap opportunities (typically five 20-minute trials separated by two-hour intervals) and is usually performed the day after a nocturnal polysomnogram (PSG) with adequate sleep.

    The Maintenance of Wakefulness Test (MWT) is a related facility-based measure of the ability to stay awake, generally consisting of four 40-minute trials using a protocol similar to the MSLT but focused on wakefulness and often used to assess treatment efficacy or safety concerns about wakefulness.

    Interpretation of MSLT requires adjunctive information when available (nocturnal PSG, clinical history including cataplexy, and in select pediatric cases CSF hypocretin-1) and relies on objective metrics such as mean sleep latency and the count of SOREMPs to support diagnostic conclusions.

    Definitions

    MSLT — Multiple Sleep Latency Test
    DefinitionMultiple Sleep Latency Test (MSLT): facility-based daytime study using multiple nap trials to objectively assess sleep tendency by measuring minutes to fall asleep and presence of sleep-onset REM periods (SOREMPs)
    ProtocolRoutine MSLT involves five 20-minute nap trials separated by two-hour intervals, typically performed the day after a nocturnal polysomnography with at least six hours of sleep
    Measurements recordedOnset of sleep and REM, along with heartbeat and chin movements; EEG, EOG, and chin EMG channels recorded for sleep staging
    MWT — Maintenance of Wakefulness Test
    DefinitionMaintenance of Wakefulness Test (MWT): facility-based study to measure an individual's ability to stay awake and alert over defined trial periods
    Protocol
    Policy Summary
    PayerAetna
    PolicyMultiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT)
    Policy CodePolicy 0330
    Change TypeAnnual review — no material changes
    Effective DateApr 20, 1999
    Last ReviewMay 2, 2023
    Next Review DateMar 28, 2024
    Key ActionSubmit CPT 95805 only when selection criteria in the policy are met (MSLT/MWT covered for evaluation of narcolepsy or suspected idiopathic hypersomnia).
    SourceLink
    On This Page
    Coverage Criteria for MSLT and MWTCoding and Diagnostic ThresholdsProvider Actions, Billing, and Denial RiskBackground and ScopeDefinitions

    Listed among indications lacking established effectiveness.

    Investigational indications: Circadian rhythm disorders.

    Listed among indications lacking established effectiveness.

    Investigational indications: Evaluation of uncomplicated parasomnias (e.g., disorders of arousal, bruxism, enuresis, nightmares, sleep talking).

    Listed among indications lacking established effectiveness.

    Investigational indications: Evaluation of the effectiveness of modafinil therapy in narcolepsy.

    Listed among indications lacking established effectiveness.

    Investigational indications: Insomnia.

    Listed among indications lacking established effectiveness.

    Investigational indications: Neurologic disorders other than narcolepsy (e.g., dementia, Parkinson's disease).

    Listed among indications lacking established effectiveness.

    Investigational indications: Obstructive sleep apnea syndrome (including for routine initial evaluation or assessment after CPAP therapy).

    Listed among indications lacking established effectiveness.

    Investigational indications: Psychiatric hypersomnolence.

    Listed among indications lacking established effectiveness.

    Investigational indications: Restless leg syndrome.

    Listed among indications lacking established effectiveness.

    Investigational indications: Other indications not listed as medically necessary in the policy.

    List is not all-inclusive; other non-listed uses are considered investigational.

    < 8 mins (adult comparator)

    Interpretation should consider heterogeneity and limited discriminative value in psychiatric populations.

    Evidence sourceROC analysis in pediatric cohort showed AUC = 0.975 for >= 2 SOREMPs; validated against CSF hypocretin-1 deficiency and cataplexy
    Clinical implicationTwo or more SOREMPs during MSLT are a valid marker for pediatric narcolepsy type 1 when considered with PSG and clinical data
    Adult pathological sleepiness cut-point (comparator)
    Adult pathological sleepiness cut-pointMean sleep latency < 8 minutes on MSLT is the commonly used cut-point to define pathologic sleepiness in adults (cited comparator)
    Observed limitationIn psychiatric hypersomnolence, ~25% of patients demonstrated mean sleep latency below 8 minutes, indicating heterogeneity and limited specificity
    Interpretation noteAdult <8 min cut-point is used as comparator but pediatric validation produced a slightly different optimal threshold

    Restrictions on repeat MSLT/MWT

    Repeat MSLT or MWT is not routinely covered; repeat testing is allowed only when the initial test was invalid or uninterpretable, was affected by extraneous circumstances or inappropriate study conditions, or earlier testing did not provide polygraphic confirmation for suspected narcolepsy.

    • Repeat testing permitted if: initial test invalid/uninterpretable; or initial test affected by extraneous circumstances or inappropriate study conditions; or earlier MSLT/MWT lacked polygraphic confirmation.
    Note

    Optimize anti‑parkinsonian therapy before disorder‑specific testing

    For Parkinson's disease–related sleep complaints, management typically begins with optimization of anti‑parkinsonian (dopaminergic) therapy before initiating disorder‑specific testing such as MSLT/MWT.

    • No step‑therapy rules for MSLT/MWT are specified, but PD sleep disorder care should start with medication optimization and screening questionnaires, then referral/testing as needed.
    Documentation Required

    Required facility‑based study conditions and nap trial protocol

    MSLT and MWT should be performed as facility‑based studies after a nocturnal polysomnography (PSG) with adequate sleep; routine MSLT uses five 20‑minute nap trials separated by two‑hour intervals, while MWT typically uses four 40‑minute trials with a similar protocol.

    • Nightly PSG should show at least six hours of sleep prior to daytime testing.
    • MSLT: five 20‑minute nap trials separated by two hours.
    • MWT: four 40‑minute trials; protocol similar to MSLT but assesses ability to stay awake.
    Documentation Required

    Required supporting diagnostic data for interpreting MSLT

    Provide diagnostic elements required to interpret MSLT: report mean sleep latency and number of SOREMPs; when available, include adjunctive nocturnal PSG data and, in pediatric evaluation, CSF hypocretin‑1 and cataplexy status as relevant.

    • Include mean sleep latency and count of SOREMPs from MSLT.
    • Attach prior nocturnal PSG results (e.g., sleep duration and staging) used to exclude other causes of sleepiness.
    • In pediatric cases, include CSF hypocretin‑1 results and cataplexy status when available to support NT1 diagnosis.
    Denial Risk

    Denial risk for unsupported repeat testing

    Denials are likely if repeat MSLT or MWT are requested without meeting exception conditions; repeat testing is considered not medically necessary unless the initial study was invalid/uninterpretable, affected by extraneous circumstances or inadequate study conditions, or lacked polygraphic confirmation for suspected narcolepsy.

    • Document the specific exception that justifies repeat testing (invalid result, extraneous circumstances/inadequate conditions, or need for polygraphic confirmation).
    Note

    No explicit authorization/denial procedures specified in policy

    No explicit payer procedural authorization triggers or denial processes are described in the policy text; the policy cites practice parameters and references as the evidentiary basis for coverage decisions rather than specifying separate authorization procedures.

    • Use cited practice parameters and references (AASM guidance, AIM, and listed studies) to support medical necessity determinations.
    • No separate administrative prior‑authorization workflow is defined in these chunks.
    MWT typically comprises four 40-minute trials (protocol similar to MSLT) performed after a nocturnal PSG to evaluate wakefulness and therapy efficacy or safety concerns
    Typical usesUsed to assess treatment effectiveness or determine if inability to stay awake poses a public or personal safety concern
    SOREMP — Sleep-Onset REM Period
    DefinitionSOREMP (sleep-onset REM period): occurrence of REM sleep at the time of sleep onset during MSLT or PSG; counted during nap trials
    Diagnostic roleNumber of SOREMPs on MSLT is used as a diagnostic marker for narcolepsy type 1 (>= 2 SOREMPs supported pediatric NT1 in cited study)
    Measurement contextSOREMPs are identified during MSLT nap trials alongside measures of sleep onset and recorded with standard sleep staging channels
    Mean sleep latency — definition and diagnostic role
    DefinitionMean sleep latency: the average time (in minutes) it takes a patient to fall asleep across MSLT nap opportunities
    Role as markerUsed as an objective marker of pathological sleepiness; pediatric NT1 study identified <= 8.2 mins as optimal cutoff, while adult practice commonly references < 8 mins
    InterpretationMean sleep latency should be interpreted with adjunctive data (nocturnal PSG, CSF hypocretin-1, clinical features such as cataplexy) for accurate diagnosis